Drug Approval | January 26, 2024
Zydus receives USFDA’s final approval for Gabapentin Tablets, 300 mg and 600 mg
Gabapentin is indicated for the management of Postherpetic Neuraligia
Gabapentin is indicated for the management of Postherpetic Neuraligia
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
The matter of Arbitration between Shilpa Medicare Limited and Celltrion towards supply and distribution agreement
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
Pimavanserin is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson disease psychosis
The PAI was conducted for two drug product applications (ANDAs) filed from this facility
The certification underscores Venus Remedies Limited's adherence to stringent quality control measures
PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phase I and II clinical trials of AB001 from their facility in New York
Subscribe To Our Newsletter & Stay Updated
